CN105106129A - Pharmaceutical lansoprazole composite granules for treating digestive system diseases - Google Patents
Pharmaceutical lansoprazole composite granules for treating digestive system diseases Download PDFInfo
- Publication number
- CN105106129A CN105106129A CN201510506220.6A CN201510506220A CN105106129A CN 105106129 A CN105106129 A CN 105106129A CN 201510506220 A CN201510506220 A CN 201510506220A CN 105106129 A CN105106129 A CN 105106129A
- Authority
- CN
- China
- Prior art keywords
- lansoprazole
- weight portion
- granule
- impurity
- digestive system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to pharmaceutical lansoprazole composite granules for treating digestive system diseases and belongs to the technical field of medicine. The granules are made from lansoprazole, cane sugar, anhydrous sodium carbonate, croscarmellose sodium, nordihydroguaiaretic acid, 95% ethyl alcohol and talcum powder. The lansoprazole is a new crystal form compound, an X-ray powder diffraction pattern of the lansoprazole measured by using Cu-Ka ray is shown in figure 1, the lansoprazole is different from those reported in the prior art, experiments show that the lansoprazole, the new crystal form compound, provided by the invention has no impurity E, in the lansoprazole, the contents of impurity A and impurity B are evidently decreased and slightly change over storage time, the lansoprazole has good fluidity and evidently improved solubility, and the lansoprazole granules made using the new crystal form compound are good in stability and low in impurity content.
Description
Technical field
The invention belongs to medical art, relate to a kind of medicine Lansoprazole composition granule for the treatment of digestive system disease.
Background technology
The benzimidazoles derivative with antiacid effect that lansoprazole is developed in December, 1991 by Japanese Wu Tian company, it acts on the H+-K+-ATP enzyme of parietal cell, the H+ of parietal cell can not be transported in stomach go, so that gastric acid amount greatly reduces in gastric juice, be used for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis, and be used for eliminating pylorus.
Lansoprazole is novel proton pump inhibitor, it is the upgraded product of omeprazole, lansoprazole is because importing fluorine at pyridine ring 4 side chains and have trifluoro ethoxy substituent group, make the comparatively omeprazole raising more than 30% of its bioavailability, lipotropy is also better than omeprazole, therefore this product promptly can play drug effect through parietal cell film changes sulfenic acids and time sulfonyl derivative in acid condition, the bacteriostatic activity of HP is risen to four times of omeprazole.
A lot of crystal formations of lansoprazole are disclosed, as the 1.5 crystal types (II type) of the anhydrous crystal forms (I type) and lansoprazole that disclose lansoprazole in CN1355798A in prior art.Describe lansoprazole A crystal formation and B crystal form in US2009/0018339A1, in fact, B crystal form is unstable, is metastable-state crystal, can experience solid-to-solid transition under certain condition, forms A crystal formation.
CN102558154A discloses a kind of lansoprazole crystalline compounds, and the X-ray powder diffraction pattern represented with the 2 θ ± 0.2 ° angle of diffraction demonstrates characteristic diffraction peak at 5.8 °, 7.5 °, 9.1 °, 11.8 °, 12.1 °, 12.8 °, 13.3 °, 15.6 °, 16.7 °, 18.3 °, 20.4 °, 25.7 °, 26.8 ° and 31.5 ° of places.
CN102180866A discloses M crystal formation and the N crystal form of lansoprazole, and wherein the X-ray powder diffraction of M crystal formation at angle of diffraction 2 θ is: 6.519,9.373,9.989,10.548,13.123,14.298,14.914,15.642,18.104,18.720,19.672,20.231,24.205,25.492,27.899 time there is characteristic peak; The X-ray powder diffraction of N crystal form at angle of diffraction 2 θ is: 5.438,7.062,8.230,9.216,11.022,11.789,12.610,13.541,20.603,21.862,26.242 time there is characteristic peak.
CN1681802A discloses three kinds of crystalline solid form of lansoprazole, and called after D, E and F type, also discloses the preparation method of these crystalline solid form of lansoprazole simultaneously respectively.
CN103664889A also discloses a kind of Lansoprazole crystal compound.
Lansoprazole has a chiral centre sulphur atom, therefore has two optical isomers.Research shows that the lansoprazole drug effect of (R)-configuration is obviously better than lansoprazole raceme, and optically active lansoprazole toxic and side effects is lower than raceme.
But according to the chemical constitution feature of lansoprazole, lansoprazole is being produced, is being deposited easy generation following impurity A, impurity B and impurity E in process, and these trace impurities can affect drug quality.Although some crystal formation of above-mentioned lansoprazole improves its hygroscopicity, dissolubility or stability to a certain extent, the present inventor's its result after the impurity of some crystal formation above-mentioned being carried out to investigation is unsatisfactory.
The present inventor starts with from the research of lansoprazole solid chemical substance existence, has prepared a kind of new compound of Lansoprazole crystal through a large amount of tests.
The lansoprazole of prior art, owing to having stronger hygroscopicity, causes its mobility bad, is unfavorable for the operation of production process; And due to almost insoluble in water, belong to low solubility, Thief zone class medicine, dissolution rate is the rate-limiting step that it absorbs.Directly affect the speed of onset, the power of drug effect due to dissolution rate and hold time, therefore, the dissolution rate improving insoluble drug usually becomes the first step improving its oral administration biaavailability.The present invention finds by test the dissolution that Lansoprazole crystal compound provided by the present invention has good mobility and significantly improves further.
Some crystal formation of the lansoprazole that the preparation method that prior art provides obtains improves from stability, hygroscopicity or dissolubility aspect mostly.But according to the chemical constitution feature of lansoprazole, lansoprazole in production, deposit in process and easily produce impurity A, impurity B and impurity E, these trace impurities can affect the quality of medicine, and the impurity A of the lansoprazole that the method for prior art obtains, impurity B and impurity E are not effectively controlled.
The present inventor is after having carried out large quantifier elimination to it, obtain above-mentioned preparation method, and surprisingly find the Lansoprazole crystal compound E free from foreign meter that the above-mentioned preparation method of employing is obtained, and the content of impurity A and impurity B significantly reduces, and along with its changes of contents of prolongation of period of storage less.
The dissolution that Lansoprazole crystal compound provided by the present invention has good mobility and significantly improves is found further by test.
Compared with prior art, tool of the present invention has the following advantages:
Lansoprazole crystal compound provided by the invention E free from foreign meter, and the content of impurity A and impurity B significantly reduces, and along with its changes of contents of prolongation of period of storage is less, the dissolution that there is excellent mobility and significantly improve, the lansoprazole particles agent good stability utilizing this crystal-form compound to make, impurity content is low.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of medicine Lansoprazole composition granule for the treatment of digestive system disease.
In order to complete object of the present invention, the technical scheme of employing is:
The present invention relates to a kind of medicine Lansoprazole composition granule for the treatment of digestive system disease, described composition granule is made up of lansoprazole, sucrose, natrium carbonicum calcinatum, cross-linking sodium carboxymethyl cellulose, nor-pair of hydrogen guaiaretic acid, 95% ethanol, Pulvis Talci; Described lansoprazole is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
First optimal technical scheme of the present invention is: with parts by weight, and described composition granule is made up of the lansoprazole of 0.1-0.2 weight portion, the sucrose of 2.4-2.8 weight portion, the natrium carbonicum calcinatum of 0.5-0.7 weight portion, the cross-linking sodium carboxymethyl cellulose of 0.4-0.6 weight portion, nor-pair of hydrogen guaiaretic acid of 0.04-0.06 weight portion, 95% ethanol of 0.7-0.9 weight portion, the Pulvis Talci of 0.02-0.04 weight portion.
Second optimal technical scheme of the present invention is: with parts by weight, and described composition granule is made up of the lansoprazole of 0.15 weight portion, the sucrose of 2.6 weight portions, the natrium carbonicum calcinatum of 0.6 weight portion, the cross-linking sodium carboxymethyl cellulose of 0.5 weight portion, nor-pair of hydrogen guaiaretic acid of 0.05 weight portion, 95% ethanol of 0.8 weight portion, the Pulvis Talci of 0.03 weight portion.
3rd optimal technical scheme of the present invention is: the preparation method of described composition granule comprises the following steps:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine, pulverizes natrium carbonicum calcinatum with pulverizer and crosses 120 mesh sieves;
2) weigh according to technology preparation amount;
3) mixing granulation: the lansoprazole of recipe quantity, sucrose, natrium carbonicum calcinatum, cross-linking sodium carboxymethyl cellulose, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add 95% ethanol of recipe quantity, wet mixing 90-120 soft material second, 16 order nylon wires are arranged in oscillating granulator granulates;
4) drying and screening: boiling drier inlet temperature is controlled at 55 DEG C-60 DEG C, wet granular is placed in boiling drier, note checking exsiccator upper-lower seal situation and granule boiling situation time dry and double granule, reach uniform drying, be dried to moisture < 3.0%, granule shaking screen after drying sieved the granule got between 16 order-32 orders;
5) always mix: the Pulvis Talci of the dry granule after granulate and recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 15 minutes;
6) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
According to the chemical constitution feature of lansoprazole, lansoprazole in production, deposit in process and easily produce impurity A, impurity B and impurity E, these trace impurities can affect the quality of medicine.Prior art provide some crystal formation of lansoprazole mostly improve from stability, hygroscopicity or dissolubility aspect, its impurity is not effectively controlled.
The present inventor is after having carried out large quantifier elimination to it, obtain a kind of lansoprazole crystal compound, and surprisingly find described compound of Lansoprazole E free from foreign meter, and the content of impurity A and impurity B significantly reduces, and along with its changes of contents of prolongation of period of storage less.
The dissolution that compound of Lansoprazole provided by the present invention has good mobility and significantly improves is found further by test.
The preparation method of the lansoprazole crystal in the present composition comprises the following steps:
(1) get lansoprazole bulk drug, add in methanol, the volumetric usage of methanol is 5 times of the quality of lansoprazole, is warming up to 35 DEG C
(2) whole dissolving is stirred to;
(3) add activated carbon decolorizing, filter, obtain settled solution;
(4) settled solution is moved in pressure vessel, the pressure in pressure vessel is controlled 2.0Mpa and stir condition under drip the ethyl acetate of 5 DEG C, the mixed solvent of ether, speed of agitator controls at 35rmp, the volumetric usage of ethyl acetate, ether is 5 times of the volume of deionized water, and the volume ratio of ethyl acetate, ether is 3:1;
(5) bleed off pressure after dripping, with the speed of 5 DEG C/min, solution is cooled to-5 DEG C, leave standstill 3h, filter, washing, drying under reduced pressure, obtains lansoprazole crystal.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction that the lansoprazole crystal of the embodiment of the present invention 1 preparation uses the measurement of Cu-K alpha ray to obtain.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
the preparation of embodiment 1 lansoprazole crystal
(1) get lansoprazole bulk drug, add in methanol, the volumetric usage of methanol is 5 times of the quality of lansoprazole, is warming up to 35 DEG C
(2) whole dissolving is stirred to;
(3) add activated carbon decolorizing, filter, obtain settled solution;
(4) settled solution is moved in pressure vessel, the pressure in pressure vessel is controlled 2.0Mpa and stir condition under drip the ethyl acetate of 5 DEG C, the mixed solvent of ether, speed of agitator controls at 35rmp, the volumetric usage of ethyl acetate, ether is 5 times of the volume of deionized water, and the volume ratio of ethyl acetate, ether is 3:1;
(5) bleed off pressure after dripping, with the speed of 5 DEG C/min, solution is cooled to-5 DEG C, leave standstill 3h, filter, washing, drying under reduced pressure, obtains lansoprazole crystal.
The X-ray powder diffraction pattern that the lansoprazole crystal prepared uses the measurement of Cu-K alpha ray to obtain as shown in Figure 1.
the preparation of embodiment 2 lansoprazole particles agent
Prescription: with parts by weight, the Lansoprazole crystal compound 0.15 part that embodiment 1 is obtained, sucrose 2.4 parts, natrium carbonicum calcinatum 0.5 part, cross-linking sodium carboxymethyl cellulose 0.4 part, the nor-pair of hydrogen guaiaretic acid 0.04 part, 95% ethanol 0.7 part, Pulvis Talci 0.02 part.
Preparation method:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine, pulverizes natrium carbonicum calcinatum with pulverizer and crosses 120 mesh sieves;
2) weigh according to technology preparation amount;
3) mixing granulation: the lansoprazole of recipe quantity, sucrose, natrium carbonicum calcinatum, cross-linking sodium carboxymethyl cellulose, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add 95% ethanol of recipe quantity, wet mixing 90-120 soft material second, 16 order nylon wires are arranged in oscillating granulator granulates;
4) drying and screening: boiling drier inlet temperature is controlled at 55 DEG C-60 DEG C, wet granular is placed in boiling drier, note checking exsiccator upper-lower seal situation and granule boiling situation time dry and double granule, reach uniform drying, be dried to moisture < 3.0%, granule shaking screen after drying sieved the granule got between 16 order-32 orders;
5) always mix: the Pulvis Talci of the dry granule after granulate and recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 15 minutes;
6) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
the preparation of embodiment 3 lansoprazole particles agent
Prescription: with parts by weight, the Lansoprazole crystal compound 0.15 part that embodiment 1 is obtained, sucrose 2.6 parts, natrium carbonicum calcinatum 0.6 part, cross-linking sodium carboxymethyl cellulose 0.5 part, the nor-pair of hydrogen guaiaretic acid 0.05 part, 95% ethanol 0.8 part, Pulvis Talci 0.03 part.
Preparation method:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine, pulverizes natrium carbonicum calcinatum with pulverizer and crosses 120 mesh sieves;
2) weigh according to technology preparation amount;
3) mixing granulation: the lansoprazole of recipe quantity, sucrose, natrium carbonicum calcinatum, cross-linking sodium carboxymethyl cellulose, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add 95% ethanol of recipe quantity, wet mixing 90-120 soft material second, 16 order nylon wires are arranged in oscillating granulator granulates;
4) drying and screening: boiling drier inlet temperature is controlled at 55 DEG C-60 DEG C, wet granular is placed in boiling drier, note checking exsiccator upper-lower seal situation and granule boiling situation time dry and double granule, reach uniform drying, be dried to moisture < 3.0%, granule shaking screen after drying sieved the granule got between 16 order-32 orders;
5) always mix: the Pulvis Talci of the dry granule after granulate and recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 15 minutes;
6) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
the preparation of embodiment 4 lansoprazole particles agent
Prescription: with parts by weight, the Lansoprazole crystal compound 0.15 part that embodiment 1 is obtained, sucrose 2.8 parts, natrium carbonicum calcinatum 0.7 part, cross-linking sodium carboxymethyl cellulose 0.6 part, the nor-pair of hydrogen guaiaretic acid 0.06 part, 95% ethanol 0.9 part, Pulvis Talci 0.04 part.
Preparation method:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine, pulverizes natrium carbonicum calcinatum with pulverizer and crosses 120 mesh sieves;
2) weigh according to technology preparation amount;
3) mixing granulation: the lansoprazole of recipe quantity, sucrose, natrium carbonicum calcinatum, cross-linking sodium carboxymethyl cellulose, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add 95% ethanol of recipe quantity, wet mixing 90-120 soft material second, 16 order nylon wires are arranged in oscillating granulator granulates;
4) drying and screening: boiling drier inlet temperature is controlled at 55 DEG C-60 DEG C, wet granular is placed in boiling drier, note checking exsiccator upper-lower seal situation and granule boiling situation time dry and double granule, reach uniform drying, be dried to moisture < 3.0%, granule shaking screen after drying sieved the granule got between 16 order-32 orders;
5) always mix: the Pulvis Talci of the dry granule after granulate and recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 15 minutes;
6) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
test example 1:determination of foreign matter in stability test
Prepare 3 batch samples according to embodiment 1, be numbered 001,002,003
Reference substance 1: according to " improvement in synthesis of lansoprazole " [Liu Yanfei, Li Yongxin etc. the improvement in synthesis [J] of lansoprazole, fine-chemical intermediate, 2011, the lansoprazole fine work of method synthesis 41(3): 26-28 and 42], m.p.169-171 DEG C (decomposition).
Reference substance 2: according to the lansoprazole form D that the method for CN1681802A embodiment 2 is obtained;
Reference substance 3: commercially available lansoprazole bulk drug
Determination of foreign matter method: with reference to " in lansoprazole intestine dissolving capsule the structural identification of impurity, inspection and control " [Xia Guimin, Deng. the structural identification of impurity, inspection and control in lansoprazole intestine dissolving capsule. pharmaceutical analysis impurity, 2012,32(6): 1022-1027] in method measure each impurity content in each sample.The results are shown in Table shown in 1:
Determination of foreign matter in table 1 lansoprazole stability test
As can be seen from experimental result, medicine impurity content of the present invention is starkly lower than contrast medicine, has good stability.
test example 2: fluidity test
Method: prepare 3 batch samples according to embodiment 1, be numbered 001,002,003, sample respectively, adopt fixed funnel method, funnel is placed in the suitable height on graph paper, lansoprazole is freely flowed down from bell mouth, until the cone top formed contacts with bell mouth, measures hypotenuse and the horizontal angle (θ angle of repose) of lansoprazole accumulation horizon.The results are shown in Table shown in 2:
The fluidity test result of table 2 lansoprazole
As can be seen from experimental result, medicine of the present invention has good mobility.
test example 3: Dissolution Rate Testing
Prepare 3 batch samples according to embodiment 1, be numbered 001,002,003
Reference substance 1: according to " improvement in synthesis of lansoprazole " [Liu Yanfei, Li Yongxin etc. the improvement in synthesis [J] of lansoprazole, fine-chemical intermediate, 2011, the lansoprazole fine work of method synthesis 41(3): 26-28 and 42], m.p.169-171 DEG C (decomposition).
Reference substance 2: according to the lansoprazole form D that the method for CN1681802A embodiment 2 is obtained;
Reference substance 3: commercially available lansoprazole bulk drug
Method: different lansoprazoles is investigated dissolution according to Pharmacopoeia of the People's Republic of China version in 2010 two annex XC method second methods.With pH6.8 phosphate buffer 900mL for dissolution medium, temperature is 37 DEG C, and rotating speed is 75rmin
-1, the medication amount in each testing sample is 30mg.Adopt ultraviolet spectrophotometry to carry out dissolution determination respectively at 5,10,15,20 and 30min sampling, determined wavelength is 284nm, at 5-25mgL
-1internal linear relation is good, and the response rate, Precision Experiment all meet methodology requirement.The results are shown in Table 3:
The dissolution of table 3 lansoprazole investigates result
As can be seen from experimental result, the dissolution of medicine of the present invention is apparently higher than contrast medicine.
Claims (5)
1. treat a medicine Lansoprazole composition granule for digestive system disease, it is characterized in that: described composition granule is made up of lansoprazole, sucrose, natrium carbonicum calcinatum, cross-linking sodium carboxymethyl cellulose, nor-pair of hydrogen guaiaretic acid, 95% ethanol, Pulvis Talci; Described lansoprazole is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. the medicine Lansoprazole composition granule for the treatment of digestive system disease according to claim 1, it is characterized in that: with parts by weight, described composition granule is made up of the lansoprazole of 0.1-0.2 weight portion, the sucrose of 2.4-2.8 weight portion, the natrium carbonicum calcinatum of 0.5-0.7 weight portion, the cross-linking sodium carboxymethyl cellulose of 0.4-0.6 weight portion, nor-pair of hydrogen guaiaretic acid of 0.04-0.06 weight portion, 95% ethanol of 0.7-0.9 weight portion, the Pulvis Talci of 0.02-0.04 weight portion.
3. the medicine Lansoprazole composition granule for the treatment of digestive system disease according to claim 2, it is characterized in that: with parts by weight, described composition granule is made up of the lansoprazole of 0.15 weight portion, the sucrose of 2.6 weight portions, the natrium carbonicum calcinatum of 0.6 weight portion, the cross-linking sodium carboxymethyl cellulose of 0.5 weight portion, nor-pair of hydrogen guaiaretic acid of 0.05 weight portion, 95% ethanol of 0.8 weight portion, the Pulvis Talci of 0.03 weight portion.
4. prepare a method for the medicine Lansoprazole composition granule of the arbitrary described treatment digestive system disease of claim 1-3, it is characterized in that comprising the following steps:
1) supplementary material process: raw material lansoprazole is crossed 80 mesh sieves with oscillating sieving machine, pulverizes natrium carbonicum calcinatum with pulverizer and crosses 120 mesh sieves;
2) weigh according to technology preparation amount;
3) mixing granulation: the lansoprazole of recipe quantity, sucrose, natrium carbonicum calcinatum, cross-linking sodium carboxymethyl cellulose, nor-pair of hydrogen guaiaretic acid are added in wet mixing pelletizer, open stirring motor and be dry mixed 10 minutes, add 95% ethanol of recipe quantity, wet mixing 90-120 soft material second, 16 order nylon wires are arranged in oscillating granulator granulates;
4) drying and screening: boiling drier inlet temperature is controlled at 55 DEG C-60 DEG C, wet granular is placed in boiling drier, note checking exsiccator upper-lower seal situation and granule boiling situation time dry and double granule, reach uniform drying, be dried to moisture < 3.0%, granule shaking screen after drying sieved the granule got between 16 order-32 orders;
5) always mix: the Pulvis Talci of the dry granule after granulate and recipe quantity is joined in three-dimensional mixer, mixing velocity 12r/min, open mixer and mix 15 minutes;
6) pack: granule is joined particles packing machine intermediate package, control content uniformity and meet inner quality standard.
5. the medicine Lansoprazole composition granule for the treatment of digestive system disease according to claim 1, it is characterized in that, the preparation method of the crystal of described lansoprazole comprises the following steps:
(1) get lansoprazole bulk drug, add in methanol, the volumetric usage of methanol is 5 times of the quality of lansoprazole, is warming up to 35 DEG C
(2) whole dissolving is stirred to;
(3) add activated carbon decolorizing, filter, obtain settled solution;
(4) settled solution is moved in pressure vessel, the pressure in pressure vessel is controlled 2.0Mpa and stir condition under drip the ethyl acetate of 5 DEG C, the mixed solvent of ether, speed of agitator controls at 35rmp, the volumetric usage of ethyl acetate, ether is 5 times of the volume of deionized water, and the volume ratio of ethyl acetate, ether is 3:1;
(5) bleed off pressure after dripping, with the speed of 5 DEG C/min, solution is cooled to-5 DEG C, leave standstill 3h, filter, washing, drying under reduced pressure, obtains lansoprazole crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510506220.6A CN105106129A (en) | 2015-08-18 | 2015-08-18 | Pharmaceutical lansoprazole composite granules for treating digestive system diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510506220.6A CN105106129A (en) | 2015-08-18 | 2015-08-18 | Pharmaceutical lansoprazole composite granules for treating digestive system diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105106129A true CN105106129A (en) | 2015-12-02 |
Family
ID=54654417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510506220.6A Withdrawn CN105106129A (en) | 2015-08-18 | 2015-08-18 | Pharmaceutical lansoprazole composite granules for treating digestive system diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106129A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107056753A (en) * | 2017-06-29 | 2017-08-18 | 张德芳 | A kind of Lansoprazole crude product refining method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080057125A1 (en) * | 2005-03-17 | 2008-03-06 | Namburi Ranga R | Stable tablet dosage forms of proton pump inhibitors |
| WO2012001705A2 (en) * | 2010-06-29 | 2012-01-05 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| CN103254174A (en) * | 2013-06-05 | 2013-08-21 | 湖北济生医药有限公司 | Lansoprazole compound and pharmaceutical composition thereof |
| CN104829594A (en) * | 2015-05-15 | 2015-08-12 | 苗怡文 | Pharmaceutical lansoprazole compound for treating gastric ulcer |
-
2015
- 2015-08-18 CN CN201510506220.6A patent/CN105106129A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080057125A1 (en) * | 2005-03-17 | 2008-03-06 | Namburi Ranga R | Stable tablet dosage forms of proton pump inhibitors |
| WO2012001705A2 (en) * | 2010-06-29 | 2012-01-05 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| CN103254174A (en) * | 2013-06-05 | 2013-08-21 | 湖北济生医药有限公司 | Lansoprazole compound and pharmaceutical composition thereof |
| CN104829594A (en) * | 2015-05-15 | 2015-08-12 | 苗怡文 | Pharmaceutical lansoprazole compound for treating gastric ulcer |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107056753A (en) * | 2017-06-29 | 2017-08-18 | 张德芳 | A kind of Lansoprazole crude product refining method |
| CN107056753B (en) * | 2017-06-29 | 2019-10-25 | 张德芳 | A kind of Lansoprazole crude product refining method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7091494B2 (en) | (S) -4- (8-Amino-3- (1- (Gnat-2-inoyl) pyrrolidine-2-yl) imidazole [1,5-a] pyrazine-1-yl) -N- (pyridine-2) -Il) Solid form and formulation of benzamide | |
| CN104873511A (en) | Medical lansoprazole composition for treating gastric ulcer | |
| CN112791054B (en) | Dry granulation method of dry suspension | |
| CN105106129A (en) | Pharmaceutical lansoprazole composite granules for treating digestive system diseases | |
| CN105147687A (en) | Pharmaceutical dasatinib composition capsules for treating leukemia | |
| CN105456213B (en) | A kind of montelukast sodium tablet | |
| CN114288259B (en) | Quick-release preparation of vitamin B2 and preparation method thereof | |
| CN103494790A (en) | Oxiracetam capsule and preparation method thereof | |
| CN106748996A (en) | A kind of Sorafenib Tosylate crystal-form compound and preparation method thereof | |
| CN104958276A (en) | Pharmaceutical lansoprazole composition capsule for treating gastric ulcer | |
| CN105616368A (en) | Montelukast sodium tablet and preparation method thereof | |
| CN106749186B (en) | A kind of novel crystal forms and preparation method thereof of R-lansoprazole sodium | |
| CN104829594A (en) | Pharmaceutical lansoprazole compound for treating gastric ulcer | |
| CN105820157A (en) | Vilazodone hydrochloride crystal form and preparation method thereof | |
| CN104844576B (en) | A kind of Lansoprazole or Dexlansoprazole crystal-form compound and preparation method thereof | |
| CN104997738A (en) | Medicine lansoprazole compound dry suspension treating gastropathy | |
| CN105168153A (en) | Medicinal lansoprazole composition lyophilized powder injection for treating gastric ulcer | |
| CN105147681A (en) | Lansoprazole composition drug for resisting gastric acid secretion | |
| CN105055332A (en) | Hydroxyfasudil composition dry suspension for treating ischemic cerebrovascular diseases | |
| CN105055337A (en) | Medicament namely fasudil hydrochloride composite granules for treating cerebral ischemia | |
| CN105106206A (en) | Medicine of lansoprazole composition for treating digestive system diseases | |
| CN105106132A (en) | Pharmic tadalafil composition granules for treating urological diseases | |
| CN105596341A (en) | Succinic acid trelagliptin solid preparation and preparation method thereof | |
| CN105055367A (en) | SprycelTM composition capsule medicine for treating leukemia | |
| CN105106216A (en) | Drug tadalafil composition capsules for treating impotence of males |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151202 |